<p>Background and Scope for Management of Patients with HR+/HER2- mBC</p>

Background and Scope for Management of Patients with HR+/HER2- mBC

Survival outcomes for patients with HR+/HER2- mBC remain suboptimal, despite first-line treatment strategies with endocrine therapy (ET). Greater understanding of the biology of HR+/HER2- mBC, including the role of biomarkers like ESR1 mutations, and the development of biopsy techniques for early mutation detection, have paved the way for personalized treatment approaches. In this activity, medical oncologists discuss integrating these evidence-based advancements into practice.

Share Background and Scope for Management of Patients with HR+/HER2- mBC

Sign up to save your podcasts

Background and Scope for Management of Patients with HR+/HER2- mBC

Background and Scope for Management of Patients with HR+/HER2- mBC